Could Aimmune Therapeutics Inc (NASDAQ:AIMT) Go Up After Its Newest Short Interest Report?

May 15, 2018 - By reb123z

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Logo

The stock of Aimmune Therapeutics Inc (NASDAQ:AIMT) registered an increase of 9.49% in short interest. AIMT’s total short interest was 4.91 million shares in May as published by FINRA. Its up 9.49% from 4.49M shares, reported previously. With 409,700 shares average volume, it will take short sellers 12 days to cover their AIMT’s short positions. The short interest to Aimmune Therapeutics Inc’s float is 17.55%.

The stock decreased 1.39% or $0.42 during the last trading session, reaching $29.72. About 267,877 shares traded. Aimmune Therapeutics, Inc. (NASDAQ:AIMT) has risen 29.28% since May 15, 2017 and is uptrending. It has outperformed by 17.73% the S&P500.

Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies in the United States and Europe. The company has market cap of $1.73 billion. The Company’s lead Characterized Oral Desensitization ImmunoTherapy product candidate is AR101, an investigational biologic for the treatment of patients with peanut allergy. It currently has negative earnings. Aimmune Therapeutics, Inc. has strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics.

More recent Aimmune Therapeutics, Inc. (NASDAQ:AIMT) news were published by: Seekingalpha.com which released: “Backing Blackstone For A Decade – Cramer’s Lightning Round (4/23/18)” on April 24, 2018. Also Businesswire.com published the news titled: “Aimmune Therapeutics to Present Data on Peanut Allergy at the European Academy of Allergy and Clinical …” on May 15, 2018. Globenewswire.com‘s news article titled: “Market Trends Toward New Normal in Genuine Parts, Energizer, Arthur J. Gallagher, Aimmune Therapeutics, Roku …” with publication date: April 19, 2018 was also an interesting one.

Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


WP Twitter Auto Publish Powered By : XYZScripts.com